Actively Recruiting
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
Led by Chinese University of Hong Kong · Updated on 2026-03-19
84
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Rebleeding rate is high in hepatocellular carcinoma (HCC) patients with variceal bleeding despite conventional endoscopic therapies for esophageal and gastric varices (EV, GV). Secondary prevention of variceal rebleeding was reported to improve outcomes of HCC patients, but the optimal endoscopic approach is not well defined. In this difficult-to-manage population, variceal rebleeding rates remain substantial after conventional endoscopic therapies. n recent studies by others and our group on direct EUS-guided therapy for varices in cirrhotic patients, high technical success (90 - 100%), low post-treatment rebleeding rate (3 - 11%) and low adverse event rate (\~3%) have been reported for GV treatment by cyanoacrylate glue injection, coiling or a combination of both, and for cyanoacrylate glue injection or coiling of EV refractory to variceal band ligation (VBL). This study aims to compare rebleeding rates after secondary prevention by EUS-guided therapy or conventional endoscopic therapy in HCC patients with recent variceal bleeding.
CONDITIONS
Official Title
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Consecutive HCC patients age 18 or older with recent (within 4 weeks of the episode) esophageal or gastric variceal bleeding successfully controlled by conventional endoscopic therapies (variceal band ligation for esophageal varices or glue injection for gastric varices)
- Able to provide written informed consent to participate in the study and comply with study procedures
You will not qualify if you...
- Unable to provide written informed consent
- Contraindications for endoscopy due to underlying health conditions
- HCC patients with gastrointestinal bleeding from sources other than varices
- Refractory coagulopathy (INR greater than 1.5) or refractory low platelet count (below 50,000) despite blood transfusions
- Moribund patients with terminal illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prince of Wales Hospital, The Chinese University of Hong Kong
Shatin, New Territories, Hong Kong
Actively Recruiting
Research Team
R
Raymond S Tang, MD
CONTACT
F
Felix Sia, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here